A once-pub­lic psy­che­del­ic biotech reemerges with $103M from MPM and No­vo Hold­ings

MPM BioIm­pact and No­vo Hold­ings are among a group of in­vestors pour­ing $103 mil­lion in­to a psy­che­del­ic biotech that MPM took pri­vate last sum­mer.

Re­union Neu­ro­science, a Mor­ris­town, NJ-based biotech, un­veiled its new life as a pri­vate com­pa­ny on Thurs­day morn­ing with the Se­ries A fi­nanc­ing. It had orig­i­nal­ly tar­get­ed $80 mil­lion for the round, but in­vestor in­ter­est picked up, CEO Greg Mayes told End­points News.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER